December 2020 HOW AMISH PEOPLE INFORMED A COVID-19 CLINICAL TRIAL WITH DOUGLAS VAUGHN, MDFeaturing: Douglas Vaughan, MD
Episode SummaryA Swiss Amish community in Indiana has been the focus of ongoing studies led by Douglas Vaughan, MD. Many members of this Amish community have a gene mutation that appears to protect against biological aging. A new experimental drug that effectively lowers the level of the protein associated with this mutation, PAI-1, is now being tested as a treatment for people with COVID-19 in a phase 2 clinical trial at Northwestern.
|
Douglas Vaughan, MD
Refer a PatientNorthwestern Medicine welcomes the opportunity to partner with you in caring for your patients.
|